Iron Toxicity in Hematopoietic Stem Cell Transplantation: Strike while the Iron Is Labile

V. Pullarkat
DOI: https://doi.org/10.1159/000355827
2013-12-03
Acta Haematologica
Abstract:normal when transferrin saturation is >85%. LPI can be measured in serum by a fluorescence-based assay (FeROS, Aferrix Ltd, Tel Aviv, Israel), with levels >0.5 μmol/l being considered elevated. Profound alterations in iron metabolism occur during HSCT; it is therefore important to study the kinetics of various iron parameters during HSCT rather than simply measure body iron stores prior to transplantation. NTBI (of which LPI is a component) has been shown to rise immediately upon initiation of the conditioning regimen and to remain elevated until engraftment [3, 4] . The major cause of this spike in NTBI and LPI during the period from the initiation of conditioning until engraftment is the lack of utilization of iron by the erythron, although other factors like the release of iron from dying malignant cells may also contribute [2] . This is consistent with the drop in NTBI that coincides with a rise in the reticulocyte count. Hepcidin, the major iron regulatory hormone, is induced by inflammation and its level peaks at around day 7 after HSCT [5] . By preventing iron release from storage sites as well as absorption from the gut, hepcidin may counteract the rise in LPI to some extent. By providing readily available iron for bacterial and fungal growth, the elevation in NTBI and LPI may be a major determinant of such infections that occur early after HSCT. The study by Naoum et al. [6] in this issue of Acta Haematologica sheds important light on the pathophysiology Iron overload has been associated with adverse outcomes after hematopoietic stem cell transplantation (HSCT) in various studies [1, 2] . Besides reduced overall survival and increased nonrelapse mortality, iron overload has been implicated in predisposing to an increased risk of infections and regimen-related toxicity including sinusoidal obstruction syndrome. The role of iron overload as a major determinant of HSCT outcome is not controversial in thalassemia syndromes where it is defined by measurement of liver iron concentration in liver biopsy specimens or by magnetic resonance imaging. On the contrary, the majority of the studies examining the impact of iron overload on outcomes of HSCT for nonthalassemia indications have used pretransplant serum ferritin as a measure of iron stores for practical reasons. Hence, there has been interest in performing more direct measurement of tissue or serum iron parameters and correlating them with HSCT outcomes and complications. Iron toxicity results from generating tissue-damaging free radicals that are produced by the catalytic activity of free iron. The majority of plasma iron is bound by the carrier protein transferrin, thereby protecting tissues from iron toxicity. The small fraction of iron that is not bound to transferrin is termed non-transferrin-bound iron (NTBI). Labile plasma iron (LPI) refers to the redox-active, cell-penetrating component of NTBI in the plasma that is directly chelatable. LPI levels generally rise above Received: September 17, 2013 Accepted: September 19, 2013 Published online: December 3, 2013
What problem does this paper attempt to address?